RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Novella Clinical, a full service clinical research organization, today announced three senior executives have assumed new leadership roles within the organization.
Deborah Turunjian has been named Vice President, Oncology Clinical Development and will lead further expansion of Novella's dedicated oncology division. Previously, Ms. Turunjian served as executive leadership for Novella's business optimization and vendor management departments in addition to her oversight of western U.S. business operations. Ms. Turunjian brings over 30 years leadership experience in business operations overseeing global outsourcing and strategic partnerships in more than 25 countries. Specifically, she has more than 10 years operational management experience of Phase I, II and III global oncology trials in both sponsor and CRO organizations. Prior to joining Novella in 2010, Ms. Turunjian served as director of clinical operations for OSI Pharmaceuticals. Ms. Turunjian holds a B.S. in Nursing.
Jamie Gault has been promoted to Global Head of Regulatory Affairs and will oversee preparation of regulatory packages for agencies globally. Having joined Novella in 2012 in a senior quality assurance role, Ms. Gault has 25 years experience in regulatory roles both at sponsor and CRO organizations. Her regulatory authority interactions span drugs, biologics, cell and tissue-based products, combination products and medical devices. She has managed regulatory submissions including INDs, IDEs, NDAs, and 510(k)s. Ms. Gault holds a B.S. in Chemistry from Fairmont State College and a Regulatory Affairs Certified Credential from the Regulatory Affairs Professional Association (RAPS).
Finally, Kathleen Zajd has been named Vice President, Global Quality & Compliance. She became an integral part of the Novella senior management team as a result of Novella's acquisition of Prologue Research International in 2010. Prior to co-founding Prologue, Ms. Zajd held leadership roles in clinical operations, regulatory and quality with experience spanning more than 25 years across both service organizations and sponsor (pharmaceutical and medical device) companies. With extensive knowledge of GCPs/GLPs, ICH requirements, international directives/laws that govern the conduct of global clinical trials, she is experienced of all aspects of the clinical trial process. With widespread experience conducting and managing domestic and international audit programs, she has also successfully established and maintained corporate Quality Management Systems. Ms. Zajd holds a B.S. in Natural Sciences (Biology & Chemistry focus) from University of Pittsburgh.
Novella Clinical President and CEO Richard Staub noted, "We are fortunate to work with an extremely high caliber of professionals. I am confident we have the right people in the right positions to propel Novella into our next phase of growth."
About Novella Clinical
Novella Clinical, Inc. is a full service clinical research organization with dual headquarters in Research Triangle Park, N.C. and Stevenage, England. Celebrating its 15th anniversary, Novella serves as an active partner to the oncology, biopharma and medical device industries. Novella integrates deep clinical expertise with industry-leading technologies and a proven approach to support, streamline and expertly resource the entire product development process. For more information, visit www.novellaclinical.com.
On August 14, 2013, Novella announced the signing of an agreement to be acquired by Quintiles as a unit within the Quintiles Clinical Development group. The transaction, which is subject to standard and customary closing conditions, is expected to close later this quarter.